Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
Tevogen Bio (Nasdaq: TVGN) congratulates Professor Sten Vermund, Chairperson of its Innovation and Public Health Advisory Board, on his appointment as dean of the USF Health College of Public Health, effective January 1, 2025. Dr. Vermund will continue his role as President of the Global Virus Network (GVN), a nonprofit coalition of virologists from over 80 centers in 40 countries. The GVN focuses on combating future pandemic threats through research and development of drugs, vaccines, and treatments.
Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, expressed pride in Dr. Vermund's appointment, highlighting his contributions to public health. Dr. Vermund cited exciting opportunities at USF, a public institution innovating at many levels, as a reason for his move from Yale School of Public Health.
Tevogen Bio (Nasdaq: TVGN) congratula il Professore Sten Vermund, Presidente del suo Comitato Consultivo per l'Innovazione e la Salute Pubblica, per la sua nomina a decan dell'USF Health College of Public Health, a partire dal 1 gennaio 2025. Il Dott. Vermund continuerà a ricoprire il suo ruolo di Presidente della Global Virus Network (GVN), una coalizione senza scopo di lucro di virologi provenienti da oltre 80 centri in 40 paesi. La GVN si concentra sulla lotta contro le minacce pandemiche future attraverso la ricerca e lo sviluppo di farmaci, vaccini e trattamenti.
Ryan Saadi, MD, MPH, Fondatore e CEO di Tevogen Bio, ha espresso orgoglio per la nomina del Dott. Vermund, sottolineando i suoi contributi alla salute pubblica. Il Dott. Vermund ha citato le entusiasmanti opportunità presso l'USF, un'istituzione pubblica che innova a molti livelli, come motivo del suo trasferimento dalla Yale School of Public Health.
Tevogen Bio (Nasdaq: TVGN) felicita a profesor Sten Vermund, Presidente de su Consejo Asesor de Innovación y Salud Pública, por su nombramiento como decano de la Facultad de Salud Pública de USF, efectivo a partir del 1 de enero de 2025. El Dr. Vermund continuará desempeñando su función como Presidente de la Global Virus Network (GVN), una coalición sin fines de lucro de virólogos de más de 80 centros en 40 países. La GVN se enfoca en combatir las amenazas pandémicas futuras a través de la investigación y el desarrollo de medicamentos, vacunas y tratamientos.
Ryan Saadi, MD, MPH, Fundador y CEO de Tevogen Bio, expresó su orgullo por el nombramiento del Dr. Vermund, destacando sus contribuciones a la salud pública. El Dr. Vermund citó las emocionantes oportunidades en USF, una institución pública que innova en muchos niveles, como motivo para su traslado de la Escuela de Salud Pública de Yale.
Tevogen Bio (Nasdaq: TVGN)는 스텐 벌문드 교수에게 축하의 말을 전합니다. 그는 혁신 및 공공 보건 자문 위원회의 의장으로서 USF 보건 공공 보건 대학의 학장으로 임명되었습니다, 2025년 1월 1일부터 발효됩니다. 벌문드 박사는 글로벌 바이러스 네트워크 (GVN)의 회장 역할도 계속 수행할 예정이며, 이 네트워크는 40개국 80개 이상의 센터로부터 온 바이러스학자들로 구성된 비영리 단체입니다. GVN은 약물, 백신 및 치료법의 연구와 개발을 통해 향후 팬데믹 위협에 맞서 싸우는 데 주력하고 있습니다.
Tevogen Bio의 창립자이자 CEO인 라이언 사디 MD, MPH는 벌문드 박사의 임명에 자부심을 표하며 그의 공공 보건 분야에 대한 기여를 강조했습니다. 벌문드 박사는 예일 대학교 공공 보건 학교에서의 이동 이유로 USF의 많은 수준에서 혁신을 이루고 있는 공공 기관에서의 흥미로운 기회를 언급했습니다.
Tevogen Bio (Nasdaq: TVGN) félicite le professeur Sten Vermund, président de son conseil consultatif en innovation et santé publique, pour sa nomination en tant que doyen de la faculté de santé publique de l'USF, à compter du 1er janvier 2025. Le Dr Vermund continuera à occuper son rôle de président du Global Virus Network (GVN), une coalition à but non lucratif de virologues provenant de plus de 80 centres dans 40 pays. Le GVN se concentre sur la lutte contre les menaces pandémiques futures grâce à la recherche et au développement de médicaments, de vaccins et de traitements.
Ryan Saadi, MD, MPH, fondateur et CEO de Tevogen Bio, a exprimé sa fierté concernant la nomination du Dr Vermund, mettant en avant ses contributions à la santé publique. Le Dr Vermund a cité les opportunités passionnantes à l'USF, une institution publique innovante à de nombreux niveaux, comme raison de son départ de la Yale School of Public Health.
Tevogen Bio (Nasdaq: TVGN) gratuliert Professor Sten Vermund, Vorsitzender seines Innovations- und Öffentlichkeitsgesundheits-Ausschusses, zu seiner Ernennung zum Dekan des USF Health College of Public Health, die am 1. Januar 2025 wirksam wird. Dr. Vermund wird weiterhin die Rolle des Präsidenten des Global Virus Network (GVN) übernehmen, einer gemeinnützigen Koalition von Virologen aus über 80 Zentren in 40 Ländern. Das GVN konzentriert sich darauf, zukünftigen pandemischen Bedrohungen durch Forschung und Entwicklung von Medikamenten, Impfstoffen und Behandlungen entgegenzuwirken.
Ryan Saadi, MD, MPH, Gründer und CEO von Tevogen Bio, äußerte Stolz über die Ernennung von Dr. Vermund und hob seine Beiträge zur öffentlichen Gesundheit hervor. Dr. Vermund nannte die spannenden Möglichkeiten an der USF, einer öffentlichen Einrichtung, die auf vielen Ebenen innovativ ist, als Grund für seinen Wechsel von der Yale School of Public Health.
- Appointment of a key advisor to a prestigious academic position, potentially enhancing Tevogen Bio's reputation
- Continued association with a leading figure in public health and virology research
- None.
WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio’s Innovation and Public Health Advisory Board, on being named as the dean of the USF Health College of Public Health, effective January 1, 2025.
In addition to his new role at the University of South Florida, Dr. Vermund will continue to serve as the President of the Global Virus Network (GVN), a nonprofit coalition of human and animal virologists from more than 80 centers of excellence in 40 countries. Under his leadership, the GVN is at the forefront of combating future pandemic threats through cutting-edge research and the development of innovative drugs, vaccines, and treatments.
“The team at Tevogen Bio is honored to have Dr. Vermund as a key advisor and takes immense pride in his recent appointment. His new role at USF highlights his exceptional contributions to public health and his unwavering dedication to advancing global health initiatives,” commented Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio.
Sharing his thoughts on his new appointment, Dr. Vermund said "My time as Dean of the Yale School of Public Health was both productive and gratifying. Our alumni played a vital role in supporting us, with Dr. Ryan Saadi at the forefront. When the Global Virus Network relocated its global headquarters to Tampa, an opportunity to move to the University of South Florida presented itself. I saw exciting new opportunities at the USF Health College of Public Health, a public institution that is innovating at many levels."
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
Who is Professor Sten Vermund and what is his new role related to Tevogen Bio (TVGNW)?
How might Professor Vermund's new position at USF affect Tevogen Bio (TVGNW)?
What is the Global Virus Network and how is it related to Tevogen Bio (TVGNW)?
